About Adamis Pharmaceuticals (NASDAQ:ADMP)
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMP
CUSIPN/A
Phone858-997-2400
Debt
Debt-to-Equity Ratio0.07%
Current Ratio2.44%
Quick Ratio2.24%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.07 million
Price / Sales9.07
Cash FlowN/A
Price / CashN/A
Book Value$1.18 per share
Price / Book3.01
Profitability
EPS (Most Recent Fiscal Year)($0.90)
Net Income$-25,530,000.00
Net Margins-195.36%
Return on Equity-72.84%
Return on Assets-55.13%
Miscellaneous
Employees126
Outstanding Shares33,390,000
Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions
What is Adamis Pharmaceuticals' stock symbol?
Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."
How were Adamis Pharmaceuticals' earnings last quarter?
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) released its earnings results on Monday, November, 14th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.07. The specialty pharmaceutical company had revenue of $2.08 million for the quarter. Adamis Pharmaceuticals had a negative net margin of 195.36% and a negative return on equity of 72.84%. View Adamis Pharmaceuticals' Earnings History.
When is Adamis Pharmaceuticals' next earnings date?
What price target have analysts set for ADMP?
4 Wall Street analysts have issued 1-year price objectives for Adamis Pharmaceuticals' shares. Their forecasts range from $5.00 to $7.50. On average, they expect Adamis Pharmaceuticals' share price to reach $6.6250 in the next year. View Analyst Ratings for Adamis Pharmaceuticals.
What are Wall Street analysts saying about Adamis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (3/16/2018)
- 2. Maxim Group analysts commented, "We have not had any recent news on the launch and other developments associated with Symjepi. As a result, we are increasing our therapeutics risk cut to 30%, from 25%, in our Epinephrine Pre-Filled syringe model, commercial assumptions. In addition, we are also pushing-out our timing back for the other" pipeline products models which include APC-1000, APC-2000 and APC-5000 inhalers. The result of these changes is our price target falls to $5, from $14." (2/14/2018)
Who are some of Adamis Pharmaceuticals' key competitors?
Some companies that are related to Adamis Pharmaceuticals include CannTrust (CNTTF), ObsEva (OBSV), Zealand Pharma (ZEAL), Isotechnika Pharma (AUPH), MediciNova (MNOV), Innovate (INNT), Innate Pharma (IPHYF), Sinovac Biotech (SVA), ProMetic Life Sciences (PFSCF), Concert Pharmaceuticals (CNCE), Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Sienna Biopharmaceuticals (SNNA), Syros Pharmaceuticals (SYRS) and Cara Therapeutics (CARA).
Who are Adamis Pharmaceuticals' key executives?
Adamis Pharmaceuticals' management team includes the folowing people:
- Richard C. Williams, Independent Chairman of the Board (Age 71)
- Dennis J. Carlo Ph.D., President, Chief Executive Officer, Director (Age 71)
- Robert O. Hopkins, Chief Financial Officer, Vice President - Finance (Age 54)
- David J. Marguglio, Senior Vice President - Corporate Development, Director (Age 44)
- Karen K. Daniels, Vice President - Operations (Age 62)
- Gus Fernandez Pharm.D., Vice President - Commercial Operations (Age 54)
- Thomas Moll Ph.D., Vice President - Research (Age 49)
- William Charles Denby III, Independent Director (Age 60)
- Robert B. Rothermel, Independent Director (Age 71)
Has Adamis Pharmaceuticals been receiving favorable news coverage?
Media coverage about ADMP stock has trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adamis Pharmaceuticals earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 47.61 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Adamis Pharmaceuticals?
Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamis Pharmaceuticals' stock price today?
One share of ADMP stock can currently be purchased for approximately $3.55.
How big of a company is Adamis Pharmaceuticals?
Adamis Pharmaceuticals has a market capitalization of $125.21 million and generates $13.07 million in revenue each year. The specialty pharmaceutical company earns $-25,530,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Adamis Pharmaceuticals employs 126 workers across the globe.
How can I contact Adamis Pharmaceuticals?
Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]
MarketBeat Community Rating for Adamis Pharmaceuticals (ADMP)
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Adamis Pharmaceuticals (NASDAQ:ADMP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Adamis Pharmaceuticals in the last 12 months. Their average twelve-month price target is $6.6250, suggesting that the stock has a possible upside of 86.62%. The high price target for ADMP is $7.50 and the low price target for ADMP is $5.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.6250 | $6.50 | $10.3333 | $9.8333 |
| Price Target Upside: | 86.62% upside | 85.71% upside | 158.33% upside | 90.02% upside |
Adamis Pharmaceuticals (NASDAQ:ADMP) Consensus Price Target History
Adamis Pharmaceuticals (NASDAQ:ADMP) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Adamis Pharmaceuticals (NASDAQ:ADMP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Adamis Pharmaceuticals (NASDAQ ADMP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 12.39%
Adamis Pharmaceuticals (NASDAQ ADMP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/2/2016 | David J Marguglio | VP | Sell | 700 | $9.00 | $6,300.00 | 101,527 |  |
| 5/16/2016 | David J Marguglio | SVP | Sell | 4,000 | $8.08 | $32,320.00 | 102,227 | |
| 5/9/2016 | David J Marguglio | SVP | Sell | 4,860 | $10.00 | $48,600.00 | 106,227 | |
| 5/4/2016 | David J Marguglio | SVP | Sell | 4,860 | $9.17 | $44,566.20 | 112,227 | |
| 5/3/2016 | David J Marguglio | SVP | Sell | 1,140 | $9.00 | $10,260.00 | 117,087 | |
| 4/14/2016 | David J Marguglio | SVP | Sell | 12,000 | $7.52 | $90,240.00 | 118,227 | |
| 8/14/2015 | Robert B Rothermel | Director | Buy | 7,000 | $3.33 | $23,310.00 | | |
| 4/20/2015 | David J Marguglio | SVP | Sell | 200 | $5.00 | $1,000.00 | | |
| 4/14/2015 | David J Marguglio | SVP | Sell | 2,200 | $5.01 | $11,022.00 | | |
| 3/4/2015 | David J Marguglio | SVP | Sell | 11,800 | $7.09 | $83,662.00 | | |
| 3/2/2015 | David J Marguglio | SVP | Sell | 7,000 | $6.45 | $45,150.00 | | |
| 2/13/2015 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 12,076 | $6.41 | $77,407.16 | | |
| 2/12/2015 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 38,000 | $6.40 | $243,200.00 | | |
| 2/3/2015 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 30,000 | $6.75 | $202,500.00 | | |
| 1/5/2015 | David J Marguglio | VP | Sell | 7,000 | $6.18 | $43,260.00 | | |
| 12/30/2014 | David J Marguglio | SVP | Sell | 12,228 | $6.09 | $74,468.52 | | |
| 12/29/2014 | David J Marguglio | VP | Sell | 772 | $6.00 | $4,632.00 | | |
| 12/12/2014 | David J Marguglio | SVP | Sell | 4,000 | $5.18 | $20,720.00 | | |
| 9/2/2014 | William C Denby | Director | Buy | 2,500 | $5.06 | $12,650.00 | | |
| 8/29/2014 | Robert B Rothermel | Director | Buy | 5,500 | $4.03 | $22,165.00 | | |
| 6/2/2014 | David J Marguglio | SVP | Sell | 4,000 | $5.56 | $22,240.00 | | |
| 8/14/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 7,015 | $0.57 | $3,998.55 | | |
| 8/7/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 40,000 | $0.56 | $22,400.00 | | |
| 8/2/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 67,960 | $0.57 | $38,737.20 | | |
| 7/30/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 10,328 | $0.56 | $5,783.68 | | |
| 7/26/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 95,000 | $0.56 | $53,200.00 | | |
| 7/23/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 141,224 | $0.57 | $80,497.68 | | |
(Data available from 1/1/2013 forward)
Adamis Pharmaceuticals (NASDAQ ADMP) News Headlines
| Source: |
|
Adamis Pharmaceuticals (NASDAQ:ADMP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Adamis Pharmaceuticals (NASDAQ:ADMP) Income Statement, Balance Sheet and Cash Flow Statement
Adamis Pharmaceuticals (NASDAQ ADMP) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
